Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

Muskiet, MHA, Tonneijck, L, Smits, MM, M.H.H. Kramer (Mark), Ouwens, D.M., Hartmann, B., J.J. Holst, Touw, D.J.W., A.H.J. Danser (Jan), Joles, J.A., et al. van Raalte, DH

2020

Diabetes Care , Volume 43 - Issue 11 p. 2889- 2893

Additional Metadata
Persistent URL	doi.org/10.2337/dc20-0902, hdl.handle.net/1765/131413
Journal	Diabetes Care
Rights	no subscription
Organisation	Department of Econometrics
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Muskiet, MHA, Tonneijck, L, Smits, MM, Kramer, M., Ouwens, D.M., Hartmann, B., … van Raalte, DH. (2020). Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. Diabetes Care, 43(11), 2889–2893. doi:10.2337/dc20-0902

Publication